血β_2-微球蛋白在25例获得性免疫缺陷综合征高效抗逆转录病毒治疗疗效判断中的作用

Role of serum β2-microglobulin in monitoring the efficacy of highly active anti-retroviral therapy in 25 acquired immunodeficiency syndrome patients

目的了解血β2-微球蛋白(β2-MG)在获得性免疫缺陷综合征(AIDS)高效抗逆转录病毒治疗(HAART)疗效判断中的作用。方法25例AIDS患者接受HAART 1年。治疗前及治疗开始后第1、3、6、9和12个月底检测CD4+细胞计数、人类免疫缺陷病毒(HIV)-RNA载量和血β2-MG。对治疗前、后的数据进行配对分析和相关性分析。结果治疗第1、3、6、9和12个月时CD4+细胞计数较治疗前显著上升(P值均< 0．01),HIV-RNA载量较治疗前显著下降(P值均<0．01)。治疗第3、9和12个月时血β2-MG较治疗前亦显著下降(P<0．05或0．01)。血β2-MG与CD4+细胞计数和HIV-RNA的Person相关系数分别为-0．203和0．224(P<0．05)。结论血β2-MG在HAART疗效判断中有一定的监测作用。

Objective To learn the role of serum β2-microglobulin （β2-MG） in monitoring the efficacy of highly active anti-retroviral therapy （HAART） in immunodeficiency syndrome （AIDS）. Methods 25 acquired AIDS patients were treated with HAART for 1 year their serum β2-MG, CD4^＋ cell counts and human immunodeficiency virus （HIV）- RNA were measured before initiation of treatment and at the 1st, 3rd, 6th, 9th and 12th-month of treatment. The data was analyzed with paired-samples test and correlation analysis. Results CD4^＋ cell counts were significantly increased （P 〈 0.01） and HIV-RNA decreased （P 〈 0.01） at the 1st, 3rd, 6th, 9th and 12th month of treatment while serum β2-MG was significantly decreased （P〈 0.05 or 0. 01） at the 3rd, 9th and 12th month of treatment. Serum β2-MG does not have any correlation with CD4^＋ cell counts and HIV-RNA. Conclusion Serum β2-MG can be used in monitoring the efficacy of HAART with psuidence.